Checking tumor margins during surgery for junction cancer
Part of Cancer, Digestive system clinical trials.
This trial tests ways to check that all cancer cells are removed during surgery for cancer at the junction of the esophagus and stomach. It may help ensure the best possible surgical outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma at the junction of the esophagus and stomach (types II or III).
- Your cancer is either early stage (cT1) or more advanced (cT2 or higher).
- You are scheduled to have surgery to remove the tumor.
- You are not allergic to methylene blue or fluorescein sodium (dyes used during surgery).
- You do not have severe heart or blood vessel problems that make surgery unsafe.
- You have not been in another drug or device trial in the past month.
- You are able to follow the study plan and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
This trial compares two surgical techniques for treating a specific type of cancer at the junction of the stomach and esophagus. It aims to find which surgery offers better outcomes for patients.
This trial tests a new imaging system that helps surgeons see if cancer cells remain after breast-conserving surgery. It may reduce the need for a second surgery by giving real-time feedback on the removed tissue.
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
Hear when a new Adenocarcinoma of the Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.